ImmunityBio, Inc.: insider trades · United States · SEC (Form 4)

About ImmunityBio, Inc.

ImmunityBio, Inc. (NASDAQ: IBRX) is a U.S.-based biotechnology company listed on the NASDAQ market in the United States, focused on next-generation immunotherapies for cancer and selected infectious-disease applications. The company was founded in 2014 by Patrick Soon-Shiong, who continues to serve as Executive Chairman, and it is part of a broader Nant-linked healthcare and life-sciences ecosystem. Its corporate and operational footprint is centered in the United States, while its development and commercialization strategy is increasingly international in scope. ([immunitybio.com](https://immunitybio.com/about/?utm_source=openai)) ImmunityBio’s business model is built around a platform approach: activate and restore the patient’s immune system to produce more durable anti-tumor responses. Its lead asset is ANKTIVA® (nogapendekin alfa inbakicept), an IL-15 superagonist/immunotherapy that is already approved in the United States for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. The pipeline also includes ANKTIVA-based combinations with BCG, programs in non-small cell lung cancer (NSCLC), approaches targeting treatment-related lymphopenia, and additional cellular and vector-based immunotherapy assets under the company’s broader “Cancer BioShield” platform. ([ir.immunitybio.com](https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-continued-execution-and-sales-momentum-113?utm_source=openai)) From a competitive standpoint, ImmunityBio operates in the highly demanding oncology immunotherapy space, where differentiation depends on clinical proof, regulatory execution, and the ability to commercialize effectively. It is not yet a large profitable pharma company and remains exposed to the typical biotech risks: trial success, label expansion, reimbursement, and scale-up execution. That said, it already has a marketed product, which sets it apart from many pre-revenue biotech peers. Recent disclosures point to accelerating ANKTIVA sales, with meaningful growth in product revenue and unit volumes following the permanent U.S. J-code, indicating that commercial traction is beginning to build. ([immunitybio.com](https://immunitybio.com/immunitybio-reports-60-increase-in-revenue-in-q2-2025-with-year-to-date-sales-of-43-million-and-246-unit-growth-since-j-code-with-regulatory-updates/?utm_source=openai)) Recent headlines reinforce the transition from development-stage biotech toward a commercial and multi-jurisdictional growth story. In 2025 and early 2026, the company reported stronger revenue momentum, additional FDA-related progress, expanded access authorization for lymphopenia, and Saudi FDA approval for ANKTIVA in metastatic NSCLC after failure of standard therapies. ImmunityBio also announced a collaboration agreement with BeiGene/BeOne Medicines to support a confirmatory NSCLC Phase 3 trial. In parallel, the company raised additional capital and adjusted its balance sheet, underscoring the ongoing need to fund clinical development and commercialization expansion. ([ir.immunitybio.com](https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-reports-continued-execution-and-sales-momentum-113?utm_source=openai)) For investors, ImmunityBio remains a high-upside but high-risk biotech name: the upside case depends on ANKTIVA broadening into multiple indications, while the key risks are clinical readouts, regulatory setbacks, and execution on commercialization.